Patents by Inventor Timothy Yeatman

Timothy Yeatman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160208333
    Abstract: Disclosed are gene signatures that may be used to predict the recurrence of colorectal cancer in a human patient. These signatures can be used to determine when to treat a patient with post-operative adjuvant chemotherapy, i.e., when a high risk of colorectal cancer recurrence is predicted.
    Type: Application
    Filed: July 30, 2014
    Publication date: July 21, 2016
    Inventors: Michael Schell, Timothy Yeatman
  • Patent number: 9057108
    Abstract: A two-tiered classification system that can be integrated with the current algorithm used by pathologists for identification of the site of origin for ‘malignancy with unknown primary’ is presented. In use, morphology, immunohistochemical (IHC) studies, and microarray-based top tier gene expression classifiers first subclassify cytokeratin positive carcinomas into adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma and urothelial carcinoma. Subsequently, organ-specific IHC-markers, if available, are used in conjunction with microarray-based second tier gene expression classifiers to assign the primary site of origin to the sample. This new hybrid approach combines IHC with a hierarchy of quantitative gene expression based classifiers into an algorithmic method that can assist pathologists to further refine and support their decision making process.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: June 16, 2015
    Assignee: H. Lee Moffitt Cancer and Research Institute, Inc.
    Inventors: Timothy Yeatman, Barbara A. Centeno, Gregory C. Bloom
  • Patent number: 9037416
    Abstract: Actively dividing tumors appear to progress to a life threatening condition more rapidly than slowly dividing tumors. Assessing actively dividing tumors currently involves a manual assessment of the number of mitotic cells in a histological slide prepared from the tumor and assessed by a trained pathologist. Disclosed is a method for using cumulative information from a series of expressed genes to determine tumor prognosis. This cumulative information can be used to categorize tumor samples into high mitotic states or low mitotic states using a mathematical algorithm and gene expression data derived from microarrays or quantitative-Polymerase Chain Reaction (Q-PCR) data. The specific mathematical description outlines how the algorithm assesses the most informative subset of genes from the full list of genes during the assessment of each sample.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: May 19, 2015
    Assignees: University of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Timothy Yeatman, Steven Alan Enkemann, Steven Eschrich
  • Publication number: 20140031251
    Abstract: In one aspect, methods, markers, and expression signatures are disclosed for assessing the degree to which a cell sample has epithelial cell-like properties or mesenchymal cell-like properties. In another aspect, methods are provided for predicting cancer patient prognosis based on whether the cancer is classified as having a high or low EMT Signature Score.
    Type: Application
    Filed: November 2, 2011
    Publication date: January 30, 2014
    Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., Merck Sharp & Dohme Corp.
    Inventors: Timothy Yeatman, Andrey Loboda, Michael Nebozhyn, Hongyue Dai
  • Publication number: 20130172203
    Abstract: A two-tiered classification system that can be integrated with the current algorithm used by pathologists for identification of the site of origin for ‘malignancy with unknown primary ’ is presented. In use, morphology, immunohistochemical (IHC) studies, and microarry-based top tier gene expression classifiers first subclassify cytokeratin positive carcinomas into adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma and urothelial carcinoma. Subsequently, organ-specific IHC-markers, if available, are used in conjunction with microarray-based second tier gene expression classifiers to assign the primary site of origin to the sample. This new hybrid approach combines IHC with a hierarchy of quantitative gene expression based classifiers into an algorithmic method that can assist pathologists to further refine and support their decision making process.
    Type: Application
    Filed: September 12, 2012
    Publication date: July 4, 2013
    Applicant: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Timothy Yeatman, Barbara A. Centeno, Gregory C. Bloom
  • Patent number: 8175896
    Abstract: Computers, computer program products, and methods for identifying a plurality of subjects for a clinical trial are provided. A candidate set of molecular profiles in a stored plurality of molecular profiles are identified. Each such profile has measurements for a discriminating set of cellular constituents that match the measurements of corresponding cellular constituents in a responder set of biological samples, thereby identifying the plurality of subjects for the trial from those subjects from which the candidate set of molecular profiles were derived. Each respective molecular profile in the stored plurality of profiles has measurements of a plurality of cellular constituents from a respective biological sample in a plurality of samples obtained from a first plurality of subjects.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: May 8, 2012
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South Florida
    Inventors: William S. Dalton, Timothy Yeatman
  • Patent number: 8095389
    Abstract: Computers, computer program products, and methods for identifying a plurality of subjects for a clinical trial are provided. A candidate set of molecular profiles in a stored plurality of molecular profiles are identified. Each such profile has measurements for a discriminating set of cellular constituents that match the measurements of corresponding cellular constituents in a responder set of biological samples, thereby identifying the plurality of subjects for the trial from those subjects from which the candidate set of molecular profiles were derived. Each respective molecular profile in the stored plurality of profiles has measurements of a plurality of cellular constituents from a respective biological sample in a plurality of samples obtained from a first plurality of subjects.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: January 10, 2012
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South Florida
    Inventors: William S. Dalton, Timothy Yeatman
  • Publication number: 20110288890
    Abstract: Computers, computer program products, and methods for identifying a plurality of subjects for a clinical trial are provided. A candidate set of molecular profiles in a stored plurality of molecular profiles are identified. Each such profile has measurements for a discriminating set of cellular constituents that match the measurements of corresponding cellular constituents in a responder set of biological samples, thereby identifying the plurality of subjects for the trial from those subjects from which the candidate set of molecular profiles were derived. Each respective molecular profile in the stored plurality of profiles has measurements of a plurality of cellular constituents from a respective biological sample in a plurality of samples obtained from a first plurality of subjects.
    Type: Application
    Filed: August 8, 2011
    Publication date: November 24, 2011
    Applicants: University of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: William S. Dalton, Timothy Yeatman
  • Publication number: 20110046002
    Abstract: The invention provides a molecular marker set that can be used for prognosis of breast cancer in a patient using histologically normal tissue. The invention also provides methods for evaluating prognosis of breast cancer in a patient based on a molecular molecular signature.
    Type: Application
    Filed: November 20, 2008
    Publication date: February 24, 2011
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Timothy Yeatman, Dung-Tsa Chen, Aejaz Nasir
  • Patent number: 7879545
    Abstract: A classifier to predict cellular radiation sensitivity based on gene expression profiles in thirty-five cell lines from the NCI panel of 60 cancer cell lines (NCI-60), using a novel approach to predictive gene analysis. Three novel genes are provided, retinoblastoma binding protein 4 (RbAp48), G-protein signaling regulator 19 (RGS19) and ribose-5-phosphate isomerase A (R5PIA) whose expression values were correlated with radiation sensitivity.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: February 1, 2011
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South Florida
    Inventors: Javier F. Torres-Roca, Timothy Yeatman, Steven Eschrich
  • Publication number: 20100240540
    Abstract: Actively dividing tumors appear to progress to a life threatening condition more rapidly than slowly dividing tumors. Assessing actively dividing tumors currently involves a manual assessment of the number of mitotic cells in a histological slide prepared from the tumor and assessed by a trained pathologist. Disclosed is a method for using cumulative information from a series of expressed genes to determine tumor prognosis. This cumulative information can be used to categorize tumor samples into high mitotic states or low mitotic states using a mathematical algorithm and gene expression data derived from microarrays or quantitative-Polymerase Chain Reaction (Q-PCR) data. The specific mathematical description outlines how the algorithm assesses the most informative subset of genes from the full list of genes during the assessment of each sample.
    Type: Application
    Filed: March 22, 2010
    Publication date: September 23, 2010
    Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South Florida
    Inventors: Timothy Yeatman, Steven Alan Enkemann, Steven Eschrich
  • Publication number: 20080033658
    Abstract: Computers, computer program products, and methods for identifying a plurality of subjects for a clinical trial are provided. A candidate set of molecular profiles in a stored plurality of molecular profiles are identified. Each such profile has measurements for a discriminating set of cellular constituents that match the measurements of corresponding cellular constituents in a responder set of biological samples, thereby identifying the plurality of subjects for the trial from those subjects from which the candidate set of molecular profiles were derived. Each respective molecular profile in the stored plurality of profiles has measurements of a plurality of cellular constituents from a respective biological sample in a plurality of samples obtained from a first plurality of subjects.
    Type: Application
    Filed: July 16, 2007
    Publication date: February 7, 2008
    Inventors: William Dalton, Timothy Yeatman
  • Publication number: 20060195266
    Abstract: The present invention pertains to specific gene signatures for cancer that are used to predict survival and novel processes for identifying such gene signatures. In one embodiment, gene signatures for human colorectal cancer are identified and outcomes are linked to the specific gene signatures using significance analysis of microarrays (SAM) and support vector machines (SVM) to provide a prognosis/survival classifier.
    Type: Application
    Filed: February 25, 2005
    Publication date: August 31, 2006
    Inventor: Timothy Yeatman
  • Publication number: 20060195269
    Abstract: The invention provides a molecular marker set that can be used for prognosis of colorectal cancer in a colorectal cancer patient. The invention also provides methods and computer systems for evaluating prognosis of colorectal cancer in a colorectal cancer patient based on the molecular marker set. The invention also provides methods and computer systems for determining chemotherapy for a colorectal cancer patient and for enrolling patients in clinical trials.
    Type: Application
    Filed: May 19, 2005
    Publication date: August 31, 2006
    Inventors: Timothy Yeatman, Steven Eschrich, Gregory Bloom
  • Publication number: 20050123945
    Abstract: A classifier to predict cellular radiation sensitivity based on gene expression profiles in thirty-five cell lines from the NCI panel of 60 cancer cell lines (NCI-60), using a novel approach to predictive gene analysis. Three novel genes are provided, retinoblastoma binding protein 4 (RbAp48), G-protein signaling regulator 19 (RGS19) and ribose-5-phosphate isomerase A (R5PIA) whose expression values were correlated with radiation sensitivity.
    Type: Application
    Filed: November 4, 2004
    Publication date: June 9, 2005
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Javier Torres-Roca, Timothy Yeatman, Steven Eschrich